Belpointe Asset Management LLC Neurocrine Biosciences Inc Transaction History

Belpointe Asset Management LLC

  • $1.49 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024
BUY
$130.86 - $143.19 $507,344 - $555,147
3,877 Added 91.53%
8,113 $1.12 Million
Q1 2024

May 08, 2024
BUY
$130.4 - $143.74 $552,374 - $608,882
4,236 New
4,236 $584,000
Q1 2023

May 15, 2023
BUY
$94.11 - $123.02 $25,127 - $32,846
267 Added 54.6%
756 $76,000
Q4 2022

Feb 08, 2023
BUY
$106.72 - $127.06 $52,186 - $62,132
489 New
489 $58,000

Others Institutions Holding NBIX

# of Institutions
625
Shares Held
94.2M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Belpointe Asset Management LLC Portfolio

Follow Belpointe Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email